Amgen's cholesterol drug Repatha has been given the green light in Europe, making it the first in the new PCSK9 inhibitor class approved anywhere in the world. Repatha (evolocumab) is a human ...

The company’s Repatha (evolocumab) was added to optimised statin therapy in a phase 3 trial, and resulted in statistically significant regression of atherosclerosis in patients with coronary ...